Annual Cash & Cash Equivalents
$26.32 M
+$17.72 M+206.17%
December 31, 2023
Summary
- As of February 8, 2025, ONCY annual cash & cash equivalents is $26.32 million, with the most recent change of +$17.72 million (+206.17%) on December 31, 2023.
- During the last 3 years, ONCY annual cash & cash equivalents has risen by +$1.83 million (+7.49%).
- ONCY annual cash & cash equivalents is now -33.02% below its all-time high of $39.29 million, reached on December 31, 2010.
Performance
ONCY Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$14.51 M
-$3.64 M-20.05%
September 30, 2024
Summary
- As of February 8, 2025, ONCY quarterly cash and cash equivalents is $14.51 million, with the most recent change of -$3.64 million (-20.05%) on September 30, 2024.
- Over the past year, ONCY quarterly cash and cash equivalents has dropped by -$14.91 million (-50.68%).
- ONCY quarterly cash and cash equivalents is now -71.75% below its all-time high of $51.36 million, reached on March 31, 2011.
Performance
ONCY Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ONCY Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +206.2% | -50.7% |
| 3 y3 years | +7.5% | +68.8% |
| 5 y5 years | +161.6% | +68.8% |
ONCY Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -18.7% | +206.2% | -55.2% | +68.8% |
| 5 y | 5-year | -18.7% | +206.2% | -64.6% | +68.8% |
| alltime | all time | -33.0% | +1194.0% | -71.8% | +631.7% |
Oncolytics Biotech Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $14.51 M(-20.0%) |
| Jun 2024 | - | $18.14 M(-17.2%) |
| Mar 2024 | - | $21.91 M(-16.8%) |
| Dec 2023 | $26.32 M(+206.2%) | $26.32 M(-10.5%) |
| Sep 2023 | - | $29.41 M(+122.5%) |
| Jun 2023 | - | $13.22 M(+12.7%) |
| Mar 2023 | - | $11.73 M(+36.5%) |
| Dec 2022 | $8.60 M(-73.4%) | $8.60 M(-63.7%) |
| Sep 2022 | - | $23.66 M(-9.5%) |
| Jun 2022 | - | $26.15 M(-17.3%) |
| Mar 2022 | - | $31.63 M(-2.3%) |
| Dec 2021 | $32.36 M(+32.2%) | $32.36 M(-14.2%) |
| Sep 2021 | - | $37.70 M(-8.0%) |
| Jun 2021 | - | $40.97 M(+2.7%) |
| Mar 2021 | - | $39.90 M(+63.0%) |
| Dec 2020 | $24.48 M(+126.0%) | $24.48 M(+22.7%) |
| Sep 2020 | - | $19.95 M(-8.9%) |
| Jun 2020 | - | $21.90 M(+1.6%) |
| Mar 2020 | - | $21.55 M(+99.0%) |
| Dec 2019 | $10.83 M(+7.7%) | $10.83 M(+16.6%) |
| Sep 2019 | - | $9.29 M(-0.6%) |
| Jun 2019 | - | $9.35 M(-12.2%) |
| Mar 2019 | - | $10.65 M(+5.8%) |
| Dec 2018 | $10.06 M(+6.9%) | $10.06 M(-19.9%) |
| Sep 2018 | - | $12.55 M(-11.2%) |
| Jun 2018 | - | $14.14 M(+135.7%) |
| Mar 2018 | - | $6.00 M(-36.3%) |
| Dec 2017 | $9.41 M(+5.5%) | $9.41 M(-16.6%) |
| Sep 2017 | - | $11.28 M(-12.0%) |
| Jun 2017 | - | $12.82 M(+69.3%) |
| Mar 2017 | - | $7.58 M(-15.1%) |
| Dec 2016 | $8.93 M(-48.4%) | $8.93 M(-24.8%) |
| Sep 2016 | - | $11.88 M(-16.1%) |
| Jun 2016 | - | $14.16 M(-9.2%) |
| Mar 2016 | - | $15.59 M(-9.9%) |
| Dec 2015 | $17.31 M(+42.0%) | $17.31 M(-16.9%) |
| Sep 2015 | - | $20.83 M(-13.9%) |
| Jun 2015 | - | $24.18 M(+7.3%) |
| Mar 2015 | - | $22.54 M(+84.9%) |
| Dec 2014 | $12.19 M(-48.5%) | $12.19 M(-9.4%) |
| Sep 2014 | - | $13.45 M(-15.0%) |
| Jun 2014 | - | $15.82 M(-13.2%) |
| Mar 2014 | - | $18.23 M(-23.0%) |
| Dec 2013 | $23.69 M(+21.9%) | $23.69 M(-17.1%) |
| Sep 2013 | - | $28.57 M(-17.2%) |
| Jun 2013 | - | $34.50 M(-15.6%) |
| Mar 2013 | - | $40.86 M(+110.4%) |
| Dec 2012 | $19.42 M | $19.42 M(-26.7%) |
| Sep 2012 | - | $26.51 M(-18.9%) |
| Jun 2012 | - | $32.70 M(-26.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | $44.76 M(+38.8%) |
| Dec 2011 | $32.24 M(-17.9%) | $32.24 M(-16.9%) |
| Sep 2011 | - | $38.78 M(-19.5%) |
| Jun 2011 | - | $48.16 M(-6.2%) |
| Mar 2011 | - | $51.36 M(+30.7%) |
| Dec 2010 | $39.29 M(+27.6%) | $39.29 M(+152.0%) |
| Sep 2010 | - | $15.59 M(-28.6%) |
| Jun 2010 | - | $21.83 M(-18.3%) |
| Mar 2010 | - | $26.71 M(-13.2%) |
| Dec 2009 | $30.80 M(+410.7%) | $30.80 M(+241.0%) |
| Sep 2009 | - | $9.03 M(-12.4%) |
| Jun 2009 | - | $10.31 M(+76.7%) |
| Mar 2009 | - | $5.84 M(-3.2%) |
| Dec 2008 | $6.03 M(-10.4%) | $6.03 M(-49.4%) |
| Sep 2008 | - | $11.92 M(+48.6%) |
| Jun 2008 | - | $8.02 M(+12.3%) |
| Mar 2008 | - | $7.14 M(+6.2%) |
| Dec 2007 | $6.73 M(+124.7%) | $6.73 M(+100.9%) |
| Sep 2007 | - | $3.35 M(-48.5%) |
| Jun 2007 | - | $6.50 M(-33.7%) |
| Mar 2007 | - | $9.81 M(+227.8%) |
| Dec 2006 | $2.99 M(-0.9%) | $2.99 M(-15.5%) |
| Sep 2006 | - | $3.54 M(-45.3%) |
| Jun 2006 | - | $6.47 M(+17.3%) |
| Mar 2006 | - | $5.51 M(+82.5%) |
| Dec 2005 | $3.02 M(-70.7%) | $3.02 M(-25.1%) |
| Sep 2005 | - | $4.03 M(-37.5%) |
| Jun 2005 | - | $6.46 M(-7.7%) |
| Mar 2005 | - | $6.99 M(-32.3%) |
| Dec 2004 | $10.32 M(+407.7%) | $10.32 M(+420.8%) |
| Sep 2004 | - | $1.98 M(-13.6%) |
| Jun 2004 | - | $2.29 M(+2.2%) |
| Mar 2004 | - | $2.24 M(+10.4%) |
| Dec 2003 | $2.03 M(-61.4%) | $2.03 M(-28.0%) |
| Sep 2003 | - | $2.82 M(-71.6%) |
| Jun 2003 | - | $9.94 M(+112.4%) |
| Mar 2003 | - | $4.68 M(-11.2%) |
| Dec 2002 | $5.27 M(-43.8%) | $5.27 M(+7.4%) |
| Sep 2002 | - | $4.91 M(-25.9%) |
| Jun 2002 | - | $6.62 M(-12.0%) |
| Mar 2002 | - | $7.53 M(-19.7%) |
| Dec 2001 | $9.37 M(-20.2%) | $9.37 M(-6.7%) |
| Sep 2001 | - | $10.04 M(-8.0%) |
| Jun 2001 | - | $10.91 M(+1.3%) |
| Mar 2001 | - | $10.77 M(-8.3%) |
| Dec 2000 | $11.74 M(+275.3%) | $11.74 M(-5.8%) |
| Sep 2000 | - | $12.46 M(+7.5%) |
| Jun 2000 | - | $11.59 M(-4.2%) |
| Mar 2000 | - | $12.09 M |
| Dec 1999 | $3.13 M | - |
FAQ
- What is Oncolytics Biotech annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Oncolytics Biotech?
- What is Oncolytics Biotech annual cash & cash equivalents year-on-year change?
- What is Oncolytics Biotech quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Oncolytics Biotech?
- What is Oncolytics Biotech quarterly cash and cash equivalents year-on-year change?
What is Oncolytics Biotech annual cash & cash equivalents?
The current annual cash & cash equivalents of ONCY is $26.32 M
What is the all time high annual cash & cash equivalents for Oncolytics Biotech?
Oncolytics Biotech all-time high annual cash & cash equivalents is $39.29 M
What is Oncolytics Biotech annual cash & cash equivalents year-on-year change?
Over the past year, ONCY annual cash & cash equivalents has changed by +$17.72 M (+206.17%)
What is Oncolytics Biotech quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ONCY is $14.51 M
What is the all time high quarterly cash and cash equivalents for Oncolytics Biotech?
Oncolytics Biotech all-time high quarterly cash and cash equivalents is $51.36 M
What is Oncolytics Biotech quarterly cash and cash equivalents year-on-year change?
Over the past year, ONCY quarterly cash and cash equivalents has changed by -$14.91 M (-50.68%)